# Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

> **NCT00305695** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 160 (actual)

## Conditions studied

- Hereditary Breast and Ovarian Cancer Syndrome
- Osteoporosis
- Ovarian Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Zoledronic Acid

## Key facts

- **NCT ID:** NCT00305695
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-28
- **Primary completion:** 2011-12-22
- **Final completion:** —
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2020-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305695, "Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00305695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*